Chinese Journal of Cancer Biotherapy, Volume. 32, Issue 7, 723(2025)
Toosendanin inhibits the malignant biological behaviors of esophageal squamous cell carcinoma KYSE150 cells by downregulating HIF1A expression via the AKT/mTOR pathway
[1] [1] CHEN R, ZHENG R S, ZHANG S W,et al. Patterns and trends in esophageal cancer incidence and mortality in China: an analysis based on cancer registry data[J]. J Natl Cancer Cent, 2023, 3(1): 21-27. DOI:10.1016/j.jncc.2023.01.002.
[2] [2] SHEIKH M, ROSHANDEL G, MCCORMACK V,et al. Current status and future prospects for esophageal cancer[J/OL]. Cancers,2023, 15(3): 765[2024-10-07]. https://pubmed.ncbi.nlm.nih.gov/36765722/. DOI:10.3390/cancers15030765.
[3] [3] DEBOEVER N, JONES C M, YAMASHITA K,et al. Advances in diagnosis and management of cancer of the esophagus[J/OL]. BMJ,2024, 385: e074962[2024-10-07]. https://pubmed.ncbi.nlm.nih.gov/38830686/. DOI:10.1136/bmj-2023-074962.
[4] [4] LIU D F, LUO X Y, XIE M,et al. HNRNPC downregulation inhibits IL-6/STAT3-mediated HCC metastasis by decreasing HIF1A expression[J]. Cancer Sci, 2022, 113(10): 3347-3361. DOI:10.1111/cas.15494.
[5] [5] TANG K, TOYOZUMI T, MURAKAMI K,et al. HIF-1 stimulates the progression of oesophageal squamous cell carcinoma by activating the Wnt/-catenin signalling pathway[J]. Br J Cancer,2022, 127(3): 474-487. DOI:10.1038/s41416-022-01825-3.
[6] [6] GUO D L, JIN J, LIU J H,et al. Baicalein inhibits the progression and promotes radiosensitivity of esophageal squamous cell carcinoma by targeting HIF-1A[J]. Drug Des Devel Ther, 2022, 16:2423-2436. DOI:10.2147/DDDT.S370114.
[7] [7] HU M H, XU M, CHEN Y C,et al. Therapeutic potential of toosendanin: Novel applications of an old ascaris repellent as a drug candidate[J/OL]. Biomed Pharmacother, 2023, 167: 115541[2024-10-07]. https://pubmed.ncbi.nlm.nih.gov/37738795/. DOI:10.1016/j.biopha.2023.115541.
[8] [8] ZHANG J N, YANG F, MEI X Y,et al. Toosendanin and isotoosendanin suppress triple-negative breast cancer growthviainducing necrosis, apoptosis and autophagy[J/OL]. Chem Biol Interact, 2022, 351: 109739[2024-10-07]. https://www.sciencedirect.com/science/article/abs/pii/S000927972100377X?via%3Dihub. DOI:10.1016/j.cbi.2021.109739.
[9] [9] PEI Z, FU W, WANG G P. A natural product toosendanin inhibits epithelial-mesenchymal transition and tumor growth in pancreatic cancerviadeactivating Akt/mTOR signaling[J]. Biochem Biophys Res Commun, 2017, 493(1): 455-460. DOI:10.1016/j.bbrc.2017.08.170.
[10] [10] LORUSSO P M. Inhibition of the PI3K/AKT/mTOR pathway in solid tumors[J]. J Clin Oncol, 2016, 34(31): 3803-3815. DOI:10.1200/JCO.2014.59.0018.
[11] [11] KELLY R J. Emerging multimodality approaches to treat localized esophageal cancer[J]. J Natl Compr Canc Netw, 2019, 17(8): 1009-1014. DOI:10.6004/jnccn.2019.7337.
[12] [12] WANG L, LIU H J, LIU Y Q,et al. Potential markers of cancer stem-like cells in ESCC: a review of the current knowledge[J/OL]. Front Oncol, 2024, 13: 13248198[2024-10-07]. https://pubmed.ncbi.nlm.nih.gov/38239657/. DOI:10.3389/fonc.2023.1324819.
[13] [13] GAVIN A T, FRANCISCI S, FOSCHI R,et al. Oesophageal cancer survival in Europe: a EUROCARE-4 study[J]. Cancer Epidemiol,2012, 36(6): 505-512. DOI:10.1016/j.canep.2012.07.009.
[14] [14] HOU H F, MENG Z X, ZHAO X,et al. Survival of esophageal cancer in China: a pooled analysis on hospital-based studies from 2000 to 2018[J/OL]. Front Oncol, 2019, 9: 5488[2024-10-07]. https://pubmed.ncbi.nlm.nih.gov/31316913/. DOI:10.3389/fonc.2019.00548.
[15] [15] WANG G L, SEMENZA G L. Purification and characterization of hypoxia-inducible factor 1[J]. J Biol Chem, 1995, 270(3): 1230-1237. DOI:10.1074/jbc.270.3.1230.
[16] [16] BARSOUM I B, KOTI M, ROBERT SIEMENS D,et al. Mechanisms of hypoxia-mediated immune escape in cancer[J]. Cancer Res, 2014, 74(24): 7185-7190. DOI:10.1158/0008-5472. CAN-14-2598.
[17] [17] MA Z W, WANG L Z, CHENG J T,et al. Targeting hypoxia-inducible factor-1-mediated metastasis for cancer therapy[J]. Antioxid Redox Signal, 2021, 34(18): 1484-1497. DOI:10.1089/ars.2019.7935.
[18] [18] WANG G, FENG C C, CHU S J,et al. Toosendanin inhibits growth and induces apoptosis in colorectal cancer cells through suppression of AKT/GSK-3/-catenin pathway[J]. Int J Oncol, 2015, 47(5):1767-1774. DOI:10.3892/ijo.2015.3157.
[19] [19] SCHITO L, SEMENZA G L. Hypoxia-inducible factors: master regulators of cancer progression[J]. Trends Cancer, 2016, 2(12):758-770. DOI:10.1016/j.trecan.2016.10.016.
[20] [20] ANTONSSON B, CONTI F, CIAVATTA A,et al. Inhibition of bax channel-forming activity by Bcl-2[J]. Science, 1997, 277(5324):370-372. DOI:10.1126/science.277.5324.370.
[21] [21] ESKANDARI E, EAVES C J. Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis[J/OL]. J Cell Biol, 2022, 221(6): e2022011598[2024-10-07]. https://pubmed.ncbi.nlm.nih.gov/35551578/. DOI:10.1083/jcb.202201159.
[22] [22] GLAVIANO A, FOO A S C, LAM H Y,et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer[J/OL]. Mol Cancer, 2023, 22(1): 138[2024-10-07]. https://pubmed.ncbi.nlm.nih.gov/37596643/. DOI:10.1186/s12943-023-01827-6.
Get Citation
Copy Citation Text
CHU Yueming, ZHU Maofei, JIANG Hangyu, YUAN Qiang, LI Xing, LIU Kang, LI Lin. Toosendanin inhibits the malignant biological behaviors of esophageal squamous cell carcinoma KYSE150 cells by downregulating HIF1A expression via the AKT/mTOR pathway[J]. Chinese Journal of Cancer Biotherapy, 2025, 32(7): 723
Category:
Received: Oct. 8, 2024
Accepted: Aug. 26, 2025
Published Online: Aug. 26, 2025
The Author Email:
